Navigation Links
EXAMINE-Studie zur kardiovaskulären Sicherheit von Alogliptin erreicht primären Endpunkt: keine Erhöhung des kardiovaskulären Risikos bei Risikopatienten mit Typ-2 Diabetes
Date:9/11/2013

sgemäß den Behörden mitgeteilt.

Informationen zu Diabetes Typ 2
Diabetes Typ 2 ist die häufigste Form von Diabetes, unter der Millionen Menschen weltweit leiden. Diabetes Typ 2 ist eine fortschreitende und chronische Erkrankung; Patienten sollten ihre Erkrankung regelmäßig von einem Arzt kontrollieren lassen. Neben Diät und Bewegung müssen die Patienten häufig ein oder mehrere Medikamente einnehmen, um ihren Blutzuckerspiegel unter Kontrolle zu halten. Der „International Diabetes Federation" zufolge beliefen sich die Gesundheitsausgaben für Diabetes (Typ 1 und 2) im Jahr 2012 auf mehr als 471 Milliarden USD. Es wird geschätzt, dass dieser Betrag bis 2030 595 Milliarden USD überschreiten wird.

Informationen zu Alogliptin
Alogliptin ist ein Dipeptidylpeptidase-4-Inhibitor (DPP-4i) zur Behandlung von Diabetes Typ 2 bei Erwachsenen, in Ergänzung zu Diät und Bewegung. DPP-4is verlangsamen die Deaktivierung der Incretin-Hormone GLP-1 und GIP. Durch eine erhöhte Menge an aktiven Inkretinen kann die Bauchspeicheldrüse Insulin Glukose-abhängig sezernieren und so die Kontrolle des Blutzuckerspiegels unterstützen. Das japanische Ministerium für Gesundheit, Arbeit und Wohlfahrt ließ im April 2010 eine New Drug Application (NDA) für NESINA (Alogliptin) zur Behandlung von Diabetes Typ 2 zu; das Medikament ist in Japan unter eben diesem Markennamen erhältlich. NESINA (Alogliptin) wurde von der US-amerikanischen FDA im Januar 2013 sowohl als  Monotherapie als auch als Kombinationstherapie  (fixed-dose combination, FDC) mit Pioglitazon (OSENI) und Metformin (KAZANO) für die Behandlung von Diabetes Typ 2 bei Erwachsenen als Ergänzung zu Diät und Bewegung zugelassen. Alogliptin als Monopräparat ist gegenwärtig in Tablettendosierungen zu 6,25 mg,
'/>"/>

SOURCE Takeda Pharmaceutical Company Limited
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. American College of Chest Physicians (ACCP) und Simbionix arbeiten zusammen, um klinische Ausbildung und Patientensicherheit zu verbessern
2. Messe/Konferenz InnoPack Pharma legt den Fokus auf innovative Verpackungen für Compliance und Sicherheit
3. Takeda EXAMINE Cardiovascular Safety Outcomes Trial of Alogliptin Met Primary Endpoint of Non-Inferiority Compared to Placebo in Addition to Standard of Care Showing No Increase in Cardiovascular Risk in Type 2 Diabetes Patients at High-Risk for Car
4. Takeda Type 2 Diabetes Therapies, NESINA (alogliptin) and Fixed-Dose Combinations KAZANO (alogliptin and metformin HCl) and OSENI (alogliptin and pioglitazone), Are Now Available in Pharmacies in the United States
5. Takeda Receives FDA Approval for Three New Type 2 Diabetes Therapies, NESINA (alogliptin) and Fixed-Dose Combinations OSENI (alogliptin and pioglitazone) and KAZANO (alogliptin and metformin HCl)
6. Takeda Resubmits New Drug Applications to the United States Food and Drug Administration for Alogliptin and the Fixed-Dose Combination Alogliptin and Pioglitazone
7. National Diabetes Volunteer Leadership Council (NDVLC) Urges FDA to Enforce Stringent Accuracy Standards for Blood Glucose Monitoring Systems
8. Clinilabs Sponsors The ADAs 2013 Step Out: Walk to Stop Diabetes
9. GSMA mHealth Grand Tour Highlights How Mobile Technology Could Help Prevent 5 Million People In The EU From Developing Diabetes
10. Elcelyx Therapeutics NewMet for Type 2 Diabetes Meets Primary Endpoint in Phase 2b Study
11. Bio-Solutions Corp. Expanding in Booming Diabetes Market
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... , Jan. 23, 2015  Pete Rose, baseball,s all-time hits ... and arthritis pain reliever Myoflex, Ducere Pharma has announced. ... we are excited to have him on board with Myoflex," ... "He is a legendary player who is known across all ...
(Date:1/23/2015)... 23, 2015  iMD Companies, Inc. (ICBU) has repositioned itself as ... and grab a foothold in the hydroponic, hemp and medical ... a presence in the sector, and recently partnering with the ... hemp and medical marijuana, iMD is committing to bring its ...
(Date:1/23/2015)... Jan. 23, 2015   Leatt Corporation  (OTCQB: LEAT), a ... for all forms of sports, including extreme motor sports, ... announced today that the UISP Lega Motociclismo Lombardia, an ... riders to wear a neck brace during its racing ...
Breaking Medicine Technology:Pete Rose bets on Myoflex to relieve aches and pains 2iMD Companies Poised to Make Impact in Multi-Billion Dollar Medical Marijuana Sector With Recent Investments and Strategic Partnerships 2Leatt Announces Neck Braces Now Required For Motocross/Minicross Racing In Italy 2Leatt Announces Neck Braces Now Required For Motocross/Minicross Racing In Italy 3
... Nov. 22, 2011 Avanir Pharmaceuticals, Inc. (NASDAQ: ... the Piper Jaffray 23rd Annual Health Care Conference. ... Wednesday November 30, 2011 2:00 p.m. ET ... this presentation will be available at http://www.avanir.com . ...
... Board of Directors of BD (Becton, Dickinson and Company) (NYSE: ... per common share, an increase of 4 cents per share, or ... payable on December 30, 2011 to holders of record on December ... year 2012 would be $1.80 cents per share. ...
Cached Medicine Technology:BD Board Increases Dividend 2
(Date:1/22/2015)... The Incredible Bulk is a revolutionary method ... lean muscle by up to 30lbs in less than 12 ... HealthyandFitZone.com’s Stan Stevenson, prompting an investigative review. , “Our ... scientific diet formula that allows the body to pack on ...
(Date:1/22/2015)... Blue Cross and Blue Shield of Minnesota ... it means to “Live Fearless.” , The “Faces ... their stories about how they or someone they know has ... living in the moment. By telling these types of stories ...
(Date:1/22/2015)... York (PRWEB) January 22, 2015 The federal ... in the U.S. District Court, Southern District of West Virginia ... Inc. in that proceeding’s first bellwether trial. In an Order ... a new trial after finding that C.R. Bard had not ...
(Date:1/22/2015)... TX (PRWEB) January 22, 2015 A ... issue of experience and person-centeredness in the long-term care ... towards action across the continuum. The paper, “The Power ... Continuum,” engages perspectives and practices of the patient, resident ...
(Date:1/22/2015)... 22, 2015 Autocarinsurancebest.com has released a new ... commercial auto insurance policy . , Auto insurance quotes ... It is no longer necessary to call an agent or ... available online on a single website: http://autocarinsurancebest.com/ . , ...
Breaking Medicine News(10 mins):Health News:The Incredible Bulk: Review Examining Ben Pakulski’s Brand New Bulking Muscle Building Diet Program Released 2Health News:Blue Cross and Blue Shield of Minnesota to Showcase “Faces of Fearless” 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 3Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 4Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 3Health News:Commercial Auto Insurance Provides Several Important Features! 2
... University is collaborating on the development of a potential ... An international team of Monash and international researchers ... (MMV) Project of the Year award in recognition of ... drug candidate for clinical testing. Tanzanian President Kikwete ...
... (ALS) could lose brain function earlier than is noticeably ... care. Physicians need a method to assess these sensitive ... neuropsychological tests. Penn State College of Medicine researchers ... deficits in judgment and problem-solving in ALS patients. FTD ...
... HealthDay Reporter , TUESDAY, June 21 (HealthDay News) -- In ... U.S. Food and Drug Administration on Tuesday released nine graphic warning ... later than September 2012. One image shows a man,s ... from a hole in his neck -- the result of a ...
... HOBOKEN, NJ A recent study published in ... Coenzyme Q10 (CoQ10) combination (PycnoQ10) taken by stable heart ... strengthens the heart, increasing the blood volume ejected with ... supply to the organs improves, and patients become more ...
... with prostate cancer and who are also smokers have ... cancer-specific death, according to a study in the June ... had an increased likelihood of prostate cancer recurrence. ... aggressive prostate cancer and prostate cancer mortality. However, studies ...
... Reporter , TUESDAY, June 21 (HealthDay News) -- When arranging ... ask if there are any unlocked guns in the prospective ... with kids contain unlocked, loaded guns, experts say, and dozens ... why the Center to Prevent Youth Violence (PAX) has joined ...
Cached Medicine News:Health News:Major malaria drug research award 2Health News:Brief exam diagnoses cognitive impairment in ALS patients 2Health News:FDA Unveils Graphic Images for Cigarette Packs 2Health News:FDA Unveils Graphic Images for Cigarette Packs 3Health News:FDA Unveils Graphic Images for Cigarette Packs 4Health News:Study shows pine bark naturally improves heart function 2Health News:Study shows pine bark naturally improves heart function 3Health News:Study shows pine bark naturally improves heart function 4Health News:Being a smoker at time of prostate cancer diagnosis linked with increased risk of death 2Health News:Making Sure Child's Play Doesn't Turn Into Gunplay 2Health News:Making Sure Child's Play Doesn't Turn Into Gunplay 3Health News:Making Sure Child's Play Doesn't Turn Into Gunplay 4
... 14A and 14C have been approved. The three ... the variations in the size of the individual ... are designed to stabilize the capsule and have ... of U.S. ophthalmologists. For implatations of the ...
... is a device designed for permanent implantation ... removal surgery. It provides secondary capsular bag ... The CTR is a uniplanar, 270-degree, semi-circle ... absorbing polymethylmethacrylate (PMMA) with one manipulation eyelet ...
Stainless steel cartilage scissors....
Hannum rongeur/grasper with teth in jaws and non-locking design....
Medicine Products: